Please login to the form below

Not currently logged in


This page shows the latest mRNA-4157 news and features for those working in and with pharma, biotech and healthcare.

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

The vaccine, mRNA-4157/V940, is designed to stimulate an immune response by generating specific T-cell responses based on the unique mutational signature of a patient’s tumour, while Keytruda ... The FDA’s decision for mRNA-4157/V940 plus Keytruda

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...